Parrisa Rupe, PA
Physician Assistant · Galax, VANPI 1326486572
Payments from drug & device makers
Across 188 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$688
- Novo Nordisk$378
- AstraZeneca$300
- Vanda Pharmaceuticals Inc.$265
- Pfizer$168
- Lilly USA, LLC$135
- plus $831 from 20 others
What the payments were for
- Food & beverage$2,74099%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $688 |
| Novo Nordisk | 22 | $378 |
| AstraZeneca | 19 | $300 |
| Vanda Pharmaceuticals Inc. | 18 | $265 |
| Pfizer | 10 | $168 |
| Lilly USA, LLC | 6 | $135 |
| Amgen(2 entities) | 9 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| Abbott | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Corium, LLC | 3 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $43 |
| Dexcom, Inc. | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Convatec Inc. | 1 | $32 |
| Cranial Technologies, Inc | 2 | $28 |
| Eisai Inc. | 2 | $28 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Neurelis, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| GSK | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,765 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $89,958 |
| FarxigaDapagliflozin Propanediol | 79 | $80,249 |
| JanuviaSitagliptin Phosphate | 54 | $75,660 |
| EliquisApixaban | 54 | $53,988 |
| OzempicSemaglutide | 45 | $45,206 |
| TrulicityDulaglutide | 20 | $27,678 |
| RybelsusSemaglutide | 14 | $24,428 |
| RexultiBrexpiprazole | 14 | $22,197 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $21,438 |
| JardianceEmpagliflozin | 21 | $20,864 |
| XareltoRivaroxaban | 15 | $9,090 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,022 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,405 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $4,561 |
| Gabapentin | 214 | $3,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $135 | $117,63699 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $300 | $108,092118 claims |
| MerckJanuvia | $18 | $75,66054 claims |
| Novo NordiskOzempic, Rybelsus | $378 | $69,63459 claims |
| PfizerEliquis | $168 | $53,98854 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $105 | $22,19714 claims |
| GSKTrelegy Ellipta | $17 | $8,02212 claims |
| AbbVieSynthroid | $688 | $1,26726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Galax
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
- Juliette BeristainVirginia Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.